Nereus Pharmaceuticals - Products in Preclinical Evaluation

Clinical Trials For NPI-0052 (proteasome inhibitor)

Over 125 patients have been treated with NPI-0052. Initial single agent Phase 1 studies demonstrated the pharmacodynamic, pharmacokinetic and safety profiles of NPI-0052. Inhibition of proteasome activity up to 100% was seen without appearance of toxicities commonly associated with Velcade. Evidence of anti-cancer activity was seen in a number of tumor types such as melanoma and myeloma. Patients continue to enroll in several of these studies to confirm these initial findings.

Based on these results and the remarkable synergy seen in laboratory studies, a fourth clinical trial is being conducted to assess NPI-0052 in combination with the HDAC inhibitor vorinostat (SAHA, Zolinza) in patients with advanced pancreatic carcinoma, non-small lung carcinoma and melanoma for which further standard approved therapy is not available.

To learn more about these clinical trials please visit: www.clinicaltrials.gov.

Nereus Pharmaceutical drugs are in preclinical or clinical trail testing, and are not available by prescription from doctors. Patients can only receive these drugs if they are participating in a sponsored clinical trial.
If you are a patient and interested in entering a clinical trial, it is best that you consult your doctor regarding appropriate and available treatments for your condition, and whether or not you should enter a clinical trial. Your physician can find a description and list of participating centers for clinical trials sponsored by Nereus Pharmaceuticals, as well as other clinical trials for patients with cancer, at www.clinicaltrials.gov.
Nereus pharmaceuticals cannot respond to patient inquiries on medical matters.
Clinical trials can only be entered by contacting participating physicians and centers. Patients cannot enter clinical trials by contacting Nereus Pharmaceuticals.